BNP Paribas Financial Markets
DMAC icon

BNP Paribas Financial Markets’s DiaMedica Therapeutics DMAC Stock Holding History

BNP Paribas Financial Markets’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.5K Sell
5,894
-1,629
-22% -$10K ﹤0.01% 4981
2026
Q1 		$50.9K Buy
7,523
+83
+1% +$658 ﹤0.01% 4684
2025
Q4 		$59.2K Buy
7,440
+8
+0.1% +$60 ﹤0.01% 4603
2025
Q3 		$51.1K Sell
7,432
-11,450
-61% -$62.1K ﹤0.01% 4597
2025
Q2 		$73.6K Buy
18,882
+3,709
+24% +$14.5K ﹤0.01% 4117
2025
Q1 		$57.5K Sell
15,173
-1,627
-10% -$9.3K ﹤0.01% 4243
2024
Q4 		$91.2K Buy
16,800
+300
+2% +$1.42K ﹤0.01% 4185
2024
Q3 		$69.1K Buy
16,500
+1,300
+9% +$4.8K ﹤0.01% 3548
2024
Q2 		$44.8K Buy
15,200
+700
+5% +$1.92K ﹤0.01% 3470
2024
Q1 		$40.2K Buy
14,500
+500
+4% +$1.45K ﹤0.01% 3594
2023
Q4 		$39.8K Hold
14,000
– – ﹤0.01% 3604
2023
Q3 		$36.1K Buy
14,000
+4,200
+43% +$13.5K ﹤0.01% 3508
2023
Q2 		$42.3K Buy
9,800
+7,596
+345% +$18.4K ﹤0.01% 3513
2023
Q1 		$3.37K Buy
2,204
+1,604
+267% +$2.54K ﹤0.01% 3609
2022
Q4 		$948 Buy
+600
New +$808 ﹤0.01% 3810

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

BNP Paribas Financial Markets's DMAC Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its DiaMedica Therapeutics (DMAC) stake by 22% in Q2 2026, selling an estimated $10K and leaving 5,894 shares worth $41.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4981.

BNP Paribas Financial Markets first reported a position in DMAC in Q4 2022 and has held it in 15 quarters since. The position peaked at $91.2K in Q4 2024. 81 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • BNP Paribas Financial Markets held 5,894 shares of DiaMedica Therapeutics worth $41.5K as of Q2 2026.
  • BNP Paribas Financial Markets sold 1,629 DiaMedica Therapeutics shares in Q2 2026, an estimated $10K.
  • DiaMedica Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4981 holding.
  • BNP Paribas Financial Markets first reported a position in DiaMedica Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • BNP Paribas Financial Markets's DiaMedica Therapeutics position peaked at $91.2K in Q4 2024.
  • 81 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.